Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone phosphate
- Development stage
- Unknown
- Lead developer
- Kiora Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
EGP-437 is a proprietary, preservative-free ophthalmic solution of dexamethasone phosphate (40 mg/mL) specifically designed for non-invasive delivery via the EyeGate II Delivery System. This system utilizes transcleral iontophoresis, where a low-level electrical current drives the ionized drug molecules directly into the ocular tissues, such as the sclera and anterior segment. This modality aims to achieve high local therapeutic concentrations of the corticosteroid while minimizing systemic exposure and avoiding the complications associated with subconjunctival or intraocular injections. Developed by EyeGate Pharmaceuticals, EGP-437 has been investigated for the treatment of various inflammatory ocular conditions, including non-infectious non-necrotizing anterior scleritis and uveitis. Clinical studies, including those led by investigator John Kempen, have focused on evaluating the safety, tolerability, and preliminary efficacy of varying doses delivered through this iontophoretic method.
- Other names
- dexamethasone sodium phosphateiontophoretic dexamethasone phosphate
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone phosphate.